Monoclonal Anti-CD47 Therapy and its Haematological Effects, including Anaemia and Thrombocytopenia
Journal of Emergency Medicine, Trauma and Surgical Care · 30.08.2024 · 10 (1) · 1-8
DOI: 10.24966/ets-8798/100070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Emergency Medicine, Trauma and Surgical Care, online erschienen am 30.08.2024.
Abstract (Originalsprache)
Monoclonal anti-CD47 therapy is a new form of immunotherapy, which has been used in a clinical setting in recent years for the treatment of haematological and solid malignancies. Anti-CD47 functions by blocking the CD47-SIRPα interaction and promotes the phagocytosis of cancer cells, which attempt to invade the immune systems mechanisms via this interface.
Zitieren
APA
(2024). Monoclonal Anti-CD47 Therapy and its Haematological Effects, including Anaemia and Thrombocytopenia. Journal of Emergency Medicine, Trauma and Surgical Care, 10(1), 1-8. https://doi.org/10.24966/ets-8798/100070
Vancouver
Monoclonal Anti-CD47 Therapy and its Haematological Effects, including Anaemia and Thrombocytopenia. Journal of Emergency Medicine, Trauma and Surgical Care. 2024;10(1):1-8. doi:10.24966/ets-8798/100070
BibTeX
@article{euvimed2024,
title = {Monoclonal Anti-CD47 Therapy and its Haematological Effects, including Anaemia and Thrombocytopenia},
journal = {Journal of Emergency Medicine, Trauma and Surgical Care},
year = {2024},
volume = {10},
number = {1},
pages = {1--8},
doi = {10.24966/ets-8798/100070}
}
EUVIMED